What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
Leo J. Hofland mainly focuses on Internal medicine, Endocrinology, Somatostatin, Somatostatin receptor and Receptor.
His research in Insulin, Ghrelin, Adenoma, Pasireotide and Cabergoline are components of Internal medicine.
His work in the fields of Pituitary neoplasm, Cushing syndrome and Corticotropic cell overlaps with other areas such as Context.
His Somatostatin research includes elements of Peptide hormone and In vivo, Radioligand.
His Somatostatin receptor research includes themes of Pharmacology and Lanreotide.
Leo J. Hofland interconnects Molecular biology, Prolactin and Cell culture in the investigation of issues within Receptor.
His most cited work include:
- Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement (639 citations)
- The pathophysiological consequences of somatostatin receptor internalization and resistance (390 citations)
- [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation (288 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Endocrinology, Somatostatin, Somatostatin receptor and Receptor.
His biological study spans a wide range of topics, including Cell culture and Oncology.
As part of one scientific family, Leo J. Hofland deals mainly with the area of Endocrinology, narrowing it down to issues related to the In vivo, and often In vitro.
His Somatostatin study combines topics in areas such as Neuroendocrine tumors, Hormone, Peptide hormone and Neuropeptide.
His Somatostatin receptor study integrates concerns from other disciplines, such as Corticotropic cell, Cancer research and Pasireotide.
Leo J. Hofland has researched Receptor in several fields, including Immunohistochemistry, Gene expression, Immune system and Cell biology.
He most often published in these fields:
- Internal medicine (70.63%)
- Endocrinology (62.94%)
- Somatostatin (39.16%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (70.63%)
- Endocrinology (62.94%)
- Somatostatin (39.16%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Endocrinology, Somatostatin, Cancer research and Oncology are his primary areas of study.
He regularly ties together related areas like Gastroenterology in his Internal medicine studies.
Many of his studies on Endocrinology apply to Cell growth as well.
Leo J. Hofland is interested in Somatostatin receptor, which is a branch of Somatostatin.
His study in Cancer research is interdisciplinary in nature, drawing from both Epigenetics, Pancreatic cancer and Sirolimus.
His Oncology research incorporates themes from Sunitinib, Cancer, Pharmacotherapy, Adrenocortical carcinoma and Radiation therapy.
Between 2014 and 2021, his most popular works were:
- Whole exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1 (49 citations)
- ROLE of IGF-1 System in the Modulation of Longevity: Controversies and New Insights From a Centenarians' Perspective. (42 citations)
- Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. (42 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
Leo J. Hofland mainly investigates Internal medicine, Endocrinology, Adrenocortical carcinoma, Acromegaly and Cell growth.
As part of the same scientific family, he usually focuses on Internal medicine, concentrating on Oncology and intersecting with Pharmacotherapy.
His Endocrinology study frequently intersects with other fields, such as Adenoma.
The various areas that he examines in his Adrenocortical carcinoma study include Progressive disease, Cancer research and Malignancy.
His Cell growth research is multidisciplinary, incorporating perspectives in Protein kinase B, Downregulation and upregulation, Insulin-like growth factor 1 receptor, Everolimus and PI3K/AKT/mTOR pathway.
Receptor covers Leo J. Hofland research in Somatostatin receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
